To include your compound in the COVID-19 Resource Center, submit it here.

Keytruda pembrolizumab regulatory update

FDA granted accelerated approval to a BLA from Merck for Keytruda pembrolizumab to treat advanced melanoma in patients previously treated with Yervoy ipilimumab from Bristol-Myers Squibb Co.

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE